(Q37349172)

19 August 2017

CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients (English)

1 reference

19 August 2017

0 references

Irini Sereti

9

0 references

Richard A. Lempicki

object named as

Richard A Lempicki

2

0 references

Marjorie Bosche

7

object named as

Marjorie Bosche

1 reference

19 August 2017

8

Joseph W Adelsberger

1 reference

19 August 2017

Sarah W Read

1

1 reference

19 August 2017

Michele Di Mascio

3

1 reference

19 August 2017

Sharat Srinivasula

4

1 reference

19 August 2017

Rosanne Burke

5

1 reference

19 August 2017

William Sachau

6

1 reference

19 August 2017

Richard T Davey

10

1 reference

19 August 2017

Jorge A Tavel

11

1 reference

19 August 2017

Chiung-Yu Huang

12

1 reference

19 August 2017

Haleem J Issaq

13

1 reference

19 August 2017

Stephen D Fox

14

1 reference

19 August 2017

H Clifford Lane

15

1 reference

19 August 2017

Joseph A Kovacs

16

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

Journal of Infectious Diseases

19 August 2017

1 reference

19 August 2017

198

1 reference

19 August 2017

6

1 reference

19 August 2017

843-850

1 reference

Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744986

In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744986

IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744986

Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744986

Measurement of T-cell kinetics: recent methodologic advances

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744986

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744986

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744986

Modeling deuterated glucose labeling of T-lymphocytes

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744986

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744986

Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count?300 cells/?L who were assigned to 7.5 MIU interleukin-2

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744986

CD4+T Cell Responses to Interleukin‐2 Administration in HIV‐Infected Patients Are Directly Related to the Baseline Level of Immune Activation

3 December 2018

1 reference

12 December 2020

Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells

1 reference

12 December 2020

A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 10

1 reference

12 December 2020

Nadir CD4+ T Cell Count Predicts Response to Subcutaneous Recombinant Interleukin-2

1 reference

12 December 2020

Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial

1 reference

12 December 2020

Identifiers

DOI

10.1086/591250

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

18684102

1 reference